Foose Brice's Form 4/A amendment
AmendedInvivo Therapeutics Holdings Corp. (NVIV) · filed Feb 7, 2024
- Accession no.
- 0001974830-24-000002
- Filed
- Feb 7, 2024, 2:12 PM ET
- Trade date
- Feb 5-6, 2023
- Filing delay
- 367 days
- Rule 10b5-1 plan
- Not checked
- Original filed
- Feb 7, 2023
This filing lists 11 non-derivative transactions. Open-market sales total $123.0K. It was filed 367 days after the trade.
This amendment replaces 0001974830-24-000001 (filed Feb 7, 2024).
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Foose BriceCIK 0001974830 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 5, 2023 | InVivo Therapeutics Holdings Corp | SSaleDisposed | −37,000 | $0.31 | −$11,470 | 293,000 | Direct | |
| Feb 5, 2023 | InVivo Therapeutics Holdings Corp | SSaleDisposed | −20,000 | $0.32 | −$6,400 | 273,000 | Direct | |
| Feb 5, 2023 | InVivo Therapeutics Holdings Corp | SSaleDisposed | −13,000 | $0.30 | −$3,900 | 260,000 | Direct | |
| Feb 5, 2023 | InVivo Therapeutics Holdings Corp | SSaleDisposed | −48,000 | $0.28 | −$13,440 | 212,000 | Direct | |
| Feb 5, 2023 | InVivo Therapeutics Holdings Corp | SSaleDisposed | −12,000 | $0.25 | −$3,000 | 200,000 | Direct | |
| Feb 5, 2023 | InVivo Therapeutics Holdings Corp | SSaleDisposed | −36,000 | $0.26 | −$9,360 | 164,000 | Direct | |
| Feb 6, 2023 | InVivo Therapeutics Holdings Corp | SSaleDisposed | −8,000 | $0.34 | −$2,720 | 156,000 | Direct | |
| Feb 6, 2023 | InVivo Therapeutics Holdings Corp | SSaleDisposed | −33,000 | $0.35 | −$11,550 | 123,000 | Direct | |
| Feb 6, 2023 | InVivo Therapeutics Holdings Corp | SSaleDisposed | −35,000 | $0.36 | −$12,600 | 88,000 | Direct | |
| Feb 6, 2023 | InVivo Therapeutics Holdings Corp | SSaleDisposed | −37,000 | $0.50 | −$18,500 | 51,000 | Direct | |
| Feb 6, 2023 | InVivo Therapeutics Holdings Corp | SSaleDisposed | −51,000 | $0.59 | −$30,090 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
This amendment has no footnotes.